Provided by Tiger Trade Technology Pte. Ltd.

Janux Therapeutics, Inc.

14.16
+0.30002.16%
Post-market: 14.160.00000.00%16:20 EDT
Volume:1.03M
Turnover:14.50M
Market Cap:861.38M
PE:-7.72
High:14.29
Open:13.69
Low:13.60
Close:13.86
52wk High:35.34
52wk Low:12.12
Shares:60.83M
Float Shares:41.68M
Volume Ratio:1.03
T/O Rate:2.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8336
EPS(LYR):-1.8336
ROE:-11.48%
ROA:-9.55%
PB:0.90
PE(LYR):-7.72

Loading ...

Janux Therapeutics price target lowered to $80 from $100 at Truist

TIPRANKS
·
Mar 03

Truist Securities Adjusts PT on Janux Therapeutics to $80 From $100, Maintains Buy Rating

MT Newswires Live
·
Mar 03

Janux Therapeutics Inc : Truist Securities Cuts Target Price to $80 From $100

THOMSON REUTERS
·
Mar 03

Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating

TIPRANKS
·
Mar 02

Janux: Encouraging Early T Cell Engager Data, Broad Pipeline, and Strong Cash Runway Support Buy Rating

TIPRANKS
·
Feb 28

Janux Therapeutics price target lowered to $100 from $150 at Cantor Fitzgerald

TIPRANKS
·
Feb 27

Janux Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
Feb 27

Piper Sandler Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)

TIPRANKS
·
Feb 27

Janux Therapeutics Inc (JANX) Gets a Buy from Bank of America Securities

TIPRANKS
·
Feb 27

Janux Therapeutics price target lowered to $68 from $72 at Guggenheim

TIPRANKS
·
Feb 27

Janux Therapeutics: Rebuilding Confidence After JANX007 Setback with 2026 Clinical Catalysts and Validated PSMA x CD3 Platform

TIPRANKS
·
Feb 27

Janux Therapeutics Q4 EPS $(0.51) Beats $(0.64) Estimate

Benzinga
·
Feb 27

Janux Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Feb 27

Janux Therapeutics Q4 net loss widens on higher R&D expenses

Reuters
·
Feb 27

BRIEF-Janux Therapeutics Q4 Basic EPS USD -0.51

Reuters
·
Feb 27

Janux Therapeutics Q4 Net Income USD -42.401 Million

THOMSON REUTERS
·
Feb 27

Janux Therapeutics Q4 Operating Expenses USD 42.401 Million

THOMSON REUTERS
·
Feb 27

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Janux Therapeutics Inc (JANX) and CVS Health (CVS)

TIPRANKS
·
Feb 24

Janux Therapeutics Inc (JANX) Receives a Buy from Wedbush

TIPRANKS
·
Feb 24

Janux Therapeutics doses first patient in Phase 1 trial of JANX011 for autoimmune diseases

Reuters
·
Feb 17